{"meta":{"query_hash":"24b3db1ee63c","filters":{"venue":"Global & Regional Health Technology Assessment"},"cohort_total":2,"direct_labels_cover":0,"predictions_cover":2,"exported":2,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/24b3db1ee63c","api":"https://metacan.xera.ac/api/v1/cohort?venue=Global+%26+Regional+Health+Technology+Assessment"},"results":[{"id":"W3136654233","doi":"10.33393/grhta.2021.2193","title":"A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen","year":2021,"lang":"en","type":"article","venue":"Global & Regional Health Technology Assessment","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Health technology; Orphan drug; Agency (philosophy); Pharmacoeconomics; Regulatory agency; Health care; Intensive care medicine; Bioinformatics; Political science; Public administration","score_opus":0.3428323354606516,"score_gpt":0.5315443373492083,"score_spread":0.18871200188855664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136654233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27373695,0.46438017,0.029352147,0.027901122,0.0013919955,0.013661688,0.044485684,0.00016792769,0.14492233],"genre_scores_gemma":[0.9061617,0.058933295,0.01529567,0.003477207,0.0005160418,0.008016824,0.0057713226,0.00010191056,0.0017261392],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.7296628,0.20566803,0.024633726,0.005861022,0.030139448,0.0040350063],"domain_scores_gemma":[0.5646408,0.34119937,0.058854427,0.0069690384,0.026567644,0.0017687582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1324726,0.0011373422,0.0023467587,0.011138146,0.0008574835,0.00816411,0.0017439266,0.0025973974,0.00933086],"category_scores_gemma":[0.38855627,0.00060645014,0.0071385056,0.015331508,0.0016660969,0.0050233463,0.0036214534,0.0030950664,0.0004158026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0322297,0.0012576791,0.09610362,0.14535688,0.06554202,0.0017034695,0.010275363,0.025924202,0.0016997082,0.1501537,0.036564924,0.43318883],"study_design_scores_gemma":[0.007796981,0.018715203,0.22951293,0.18566266,0.1035118,0.004090539,0.024352342,0.019603664,0.007114013,0.046053946,0.35248232,0.0011036628],"about_ca_topic_score_codex":0.009060139,"about_ca_topic_score_gemma":0.0075196046,"teacher_disagreement_score":0.1324726,"about_ca_system_score_codex":0.016298594,"about_ca_system_score_gemma":0.011836283,"threshold_uncertainty_score":0.7005905},"labels":[],"label_agreement":null},{"id":"W4415267843","doi":"10.33393/grhta.2025.3503","title":"Estimation of patients potentially eligible for icosapent ethyl therapy in Italy through a review of literature data","year":2025,"lang":"it","type":"review","venue":"Global & Regional Health Technology Assessment","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Hypertriglyceridemia; Reimbursement; Medical prescription; Residual risk; Estimation; Triglyceride; Primary care; Clinical Practice","score_opus":0.053666433711674795,"score_gpt":0.4474086683705294,"score_spread":0.3937422346588546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415267843","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008086534,0.9868794,0.0003878306,0.0010558564,0.00011634313,0.00033422982,0.0013132452,0.000015544878,0.0018109826],"genre_scores_gemma":[0.05183072,0.9439346,0.0013972357,0.00089449604,0.00022079413,0.0005263927,0.0010043881,0.0000060108337,0.00018531409],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944194,0.0012862409,0.0023435897,0.0005051397,0.0012285311,0.00021697421],"domain_scores_gemma":[0.9724051,0.018145142,0.0070069362,0.00026397535,0.001943905,0.00023504937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006876258,0.0011786534,0.0032287869,0.028770447,0.00042383466,0.002771925,0.00129294,0.0014558232,0.004909129],"category_scores_gemma":[0.023751214,0.00072584325,0.005222352,0.018938147,0.0006372675,0.0021668547,0.0011773967,0.0006765794,0.0003988504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004872936,0.000075560114,0.023893857,0.7139658,0.006376425,0.0016427013,0.0007231368,0.00048767013,0.0003793009,0.001072525,0.006512192,0.24438353],"study_design_scores_gemma":[0.0002004887,0.00037414662,0.06488754,0.8137954,0.04676788,0.0044538453,0.0016066222,0.0006463546,0.00042797645,0.001163556,0.0655822,0.00009388421],"about_ca_topic_score_codex":0.0037930785,"about_ca_topic_score_gemma":0.0076676775,"teacher_disagreement_score":0.028770447,"about_ca_system_score_codex":0.0028592884,"about_ca_system_score_gemma":0.0060611465,"threshold_uncertainty_score":0.03636557},"labels":[],"label_agreement":null}]}